1. Scrip
  2. >>Business

Encouraging Signs For Arcus In TIGIT Race, But Gilead Holds Fire

Triplet Might Offer Arcus An Edge

 
• By Andrew McConaghie

Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet

Arcus Biosciences
Founded in 2015, Arcus is hoping anti-TIGIT candidate domvanalimab will be its big breakthrough. • Source: Alamy

Arcus Biosciences has presented early Phase II data on its TIGIT inhibitor, domvanalimab, but partner Gilead Sciences, Inc. is not yet committing to funding pivotal studies, even as an interim analyses, particularly of a triplet combination, give encouraging hints of efficacy.

TIGIT inhibitors are a promising new avenue in immuno-oncology therapy, and Arcus is in the race to bring the first...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

US Tariff Overhang Weighs on Chinese API Exports

 
• By Dexter Jie Yan

Chinese API exports to the US fell by 24% year-on-year to $255m in May, when the US and China called a truce in a previously escalating trade war.

Pharma Growth And Biotech Squeeze Will Shape Sector To 2030, Evaluate Forecasts

 
• By Andrew McConaghie

Evaluate’s five-year forecast sees steady growth for big pharma despite recent political turmoil but tougher times ahead for the ‘have nots’ of biotech.

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

More from Scrip

Vor Is Reborn With New CEO And Ambitious RemeGen Autoimmune Pact

 
• By Kevin Grogan

The biotech had been looking at options to survive since May.

Can Japan’s Richest Person Save Cell Therapy’s Future?

 
• By Lisa Takagi

With financial help from the founder of Uniqlo, Japan’s leading facility for induced pluripotent stem cells is aiming to automate production to slash costs and kick-start R&D in the field.

Post-BIO Podcast: Thoughts From The Frontlines

 
• By Sarah Karlin-Smith, Mandy Jackson, and Mary Jo Laffler

Scrip and Pink Sheet journalists reflect on the mood from Boston, the most important takeaways and what’s next for industry.